Phase 3 Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had a disabling stroke caused by a blood clot, who arrive for care within 4.5 hours of when their symptoms started (or when they were last seen to be well), and who may benefit from a clot-dissolving medication called tenecteplase given through a vein.
- People who take a type of blood-thinning medication called a DOAC, or who are planned to have a procedure to remove the clot, may still be considered for this trial.
- People who have certain medical conditions that guidelines usually flag as reasons to be cautious about clot-dissolving treatment — where a doctor's judgement is recommended — may still be eligible, as determined by the treating doctor.
- People for whom the required consent process has been completed according to the laws, regulations, and ethics requirements that apply in their country.
Who may not be able to join:
- People who have a clear medical reason why clot-dissolving medication given through a vein is completely ruled out according to current national guidelines — for example, people who are actively bleeding, have had recent brain surgery, a recent serious head injury, bleeding in or around the brain, or a condition that prevents normal blood clotting.
- People who have had a mild stroke where symptoms are not causing significant disability.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bijoy K Menon, MD, University of Calgary
Phone: 4039448107
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
A reduction of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS),
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.